NCT04526665PBCNumeric Rating ScaleElafibranorELAfibrosis
…ents (pts) with PBC based on phase III ELATIVE ® trial results (NCT04526665). We present findings from >3 years of ELA treatment in the ong…
4articles mentioning funders
4funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04526665 ×
NCT04526665
This funder is selected. Its supporting articles are shown below.
Articles mentioning NCT04526665
4 articles · page 1 of 1NCT04526665PBCElafibranor
…s are common symptoms in PBC. In the phase III ELATIVE® trial ( NCT04526665), elafibranor significantly improved biomarkers of cholestasis …
NCT04526665osteoporosisPBCelafibranorosteopenia
…iomarkers assessed to Week 52 in the phase III ELATIVE® trial ( NCT04526665).Patients (N=161) were randomized 2:1 to elafibranor 80 mg or p…
NCT04526665ElafibranorPBCFibrosis
…LF]) and biochemical markers in patients with PBC in ELATIVE® ( NCT04526665) to Week 104; NITs are also stratified by disease stage.Proport…